Guggenheim Maintains Buy Rating on Beam Therapeutics, Lowers Price Target to $51
Guggenheim has maintained its 'Buy' rating on Beam Therapeutics while adjusting the price target from $55 to $51.
Stocks · News reference
Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JonesTrading Initiates Coverage on Beam Therapeutics with Buy Rating
JonesTrading has initiated coverage on Beam Therapeutics with a 'Buy' rating and a price target of $35.
Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51
Beam Therapeutics to Present Updated BEACON Trial Data at 68th ASH Annual Meeting
Beam Therapeutics announced it will present updated clinical data from its BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel) for sickle cell disease at the upcoming American Society of Hematology (ASH) Annual Meeting.
Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30
Wedbush Adjusts Price Target on Beam Therapeutics
Wedbush maintained an Outperform rating on Beam Therapeutics while raising its price target to $30 from $28.